Eating Disorders and Psilocybin

Why Eating Disorders Are Being Studied

Eating disorders — particularly anorexia nervosa — have the highest mortality rate of any psychiatric condition. Despite decades of research, the most effective available treatments (cognitive behavioural therapy, family-based therapy, nutritional rehabilitation) leave a substantial proportion of patients with persistent symptoms and high relapse rates. The unmet need in this field has prompted researchers to explore whether psilocybin, with its demonstrated capacity to interrupt rigid thinking patterns and catalyse shifts in self-concept, might offer something existing treatments cannot.

The proposed mechanism aligns with what researchers know about eating disorders: they are characterised by extreme cognitive rigidity (particularly in anorexia), a distorted and highly negatively evaluated body image, anxiety as a core feature, and a strong sense of identity built around the illness. Psilocybin disrupts default mode network activity — the brain's self-referential processing hub — and temporarily relaxes the rigid self-narratives that maintain these patterns.

Current Research: What the Evidence Actually Shows

The evidence base is small but growing. The landmark study to date was a pilot trial at Johns Hopkins Center for Psychedelic and Consciousness Research, led by Dr. Natalie Gukasyan and published in 2023 in Nature Medicine. Ten adult women with anorexia nervosa of long duration (average 18 years ill) received two doses of psilocybin (25 mg) in a supportive therapeutic context. At one month follow-up, eight of ten participants showed clinically meaningful improvement in eating disorder psychopathology as measured by the Eating Disorder Examination Questionnaire, with several showing large effect sizes. No serious adverse events were reported.

This was an open-label trial without a control arm, meaning it cannot establish that psilocybin was causally responsible for improvement rather than the therapy, the expectation of treatment, or natural fluctuation. It is encouraging, not conclusive. The researchers note that the study population was medically stable outpatients — not people in acute phases of illness requiring hospitalisation — and that the finding cannot be generalised to the full spectrum of eating disorder presentations.

Additional trials are underway at University of California San Francisco and other centres, examining psilocybin for anorexia nervosa in larger controlled cohorts. Separate research at King's College London is examining MDMA-assisted therapy for bulimia nervosa. Binge eating disorder has received less attention, though overlapping mechanisms (impulsivity, reward dysregulation) suggest it may be another future target.

Potential Mechanisms

Reduced cognitive rigidity: Anorexia in particular is associated with an inability to update beliefs in response to new information — a form of cognitive inflexibility mediated partly by overactive default mode network processing. Psilocybin's acute disruption of this network appears to create a window during which fixed self-narratives become more fluid and amenable to revision.

Body image shifts: Clinical reports from the Johns Hopkins trial describe participants experiencing a shift in their relationship to their body during the session — perceiving it with greater acceptance or even compassion rather than the habitual disgust and critical evaluation. Whether this shift persists and how it relates to clinical outcome are open questions.

Emotional processing: Eating disorders often co-occur with or develop from early trauma, adverse experiences, or profound emotional dysregulation. Psilocybin sessions can surface and allow the processing of emotional material that has been somatised into food-restriction or purging behaviours.

Neuroplasticity: Psilocybin promotes synaptogenesis (formation of new neural connections) and BDNF expression (brain-derived neurotrophic factor, associated with neural growth). This may support the integration of new self-referential patterns during the post-session period.

Medical Risks Specific to Eating Disorders

Eating disorders create physiological vulnerabilities that are directly relevant to safety in a psilocybin session. Low body weight is associated with electrolyte imbalances — particularly low potassium and magnesium — that increase the risk of cardiac arrhythmia. Psilocybin produces a modest but real increase in heart rate and blood pressure during the acute experience; in a cardiovascularly compromised person, this could be dangerous.

Malnutrition also affects drug metabolism. A body with significantly compromised liver function, reduced body mass, and altered serum protein levels will process psilocybin differently than a healthy body, making standard dose estimates less reliable.

For these reasons, all current clinical research in this area screens participants carefully, requires minimum body weight thresholds and medical clearance, and provides on-site medical monitoring during sessions. Anyone outside a clinical trial context should treat these safety requirements as non-negotiable rather than optional.

Integration Considerations

Because eating disorders are frequently rooted in complex emotional material — perfectionism, shame, trauma, distorted interoception — the integration period requires careful therapeutic support. Sessions that surface traumatic memories or acute emotional pain need a structured therapeutic container to be processed safely. Attempting psilocybin for an eating disorder outside of professional care risks opening material without the tools to work with it.

Post-session integration therapy with a clinician who has dual expertise in eating disorders and psychedelic integration is the appropriate standard. In the absence of that dual expertise, separate working relationships with an eating disorder specialist and an integration-informed therapist, coordinating together, is a reasonable alternative.

Who Should Not Pursue This at Present

Psilocybin for eating disorders is not appropriate for: anyone in a medically acute phase of illness (dangerously low weight, active electrolyte abnormalities, cardiac complications); anyone with co-occurring psychosis or a personal or family history of schizophrenia or bipolar I disorder; anyone currently taking antidepressants that significantly attenuate psilocybin's effects (many SSRIs) or that interact dangerously with serotonergic drugs; or anyone who cannot access qualified medical supervision and integration support.

For anyone interested in participating in current research, clinicaltrials.gov lists active trials. Participation in a well-designed clinical trial is the safest and most scientifically valuable way to access psilocybin for an eating disorder at this stage of the evidence base.

Harm Reduction Guidance for Those Considering Use Outside Clinical Settings

Clinical guidance is unambiguous: psilocybin for eating disorders should only be pursued within a formal research or clinical setting. The following is harm reduction information for those who may consider it regardless — it is not an endorsement of unsupervised use.

Medical clearance is non-negotiable. Before considering any psilocybin experience, a physician should assess cardiovascular status, current weight and nutritional status, electrolyte levels (particularly potassium, sodium, and magnesium), and any medications currently prescribed. Eating disorders create measurable physiological vulnerabilities — these are not abstract concerns but concrete risks that can turn a psilocybin experience into a medical emergency.

Comorbid conditions require evaluation. Eating disorders frequently co-occur with depression, anxiety, OCD, PTSD, and substance use. Many people with eating disorders take SSRIs, which significantly reduce psilocybin's effects and introduce serotonin interaction considerations. A psychiatrist should evaluate the full clinical picture before any decision is made.

Never use alone. A trusted, sober person who is aware of the eating disorder, any medical vulnerabilities, and what to do in an emergency should be present throughout any experience. They should have contact information for a physician or crisis line and know the individual's current medication list.

Set and setting matter acutely for this population. The body-focused nature of eating disorders means that somatic experiences during a psilocybin session may be intensified or distressing. Preparation work with a therapist familiar with both eating disorders and psychedelic experiences can help build a framework for navigating body-related material. Sessions may surface intense body-image content; integration support afterward is essential rather than optional.

The Importance of Ongoing Professional Support

The post-session integration period is where the therapeutic potential of the experience is either developed or lost. For eating disorders specifically, integration involves working with the emotional and cognitive material that surfaced during the session in a structured therapeutic context. Without this, psilocybin experiences are unlikely to produce lasting change and may introduce distress without resolution.

Eating disorders have high relapse rates and require sustained, coordinated professional care. Psilocybin — even when it produces meaningful experiences — is not a standalone cure and should not be approached as one. The promising early research suggests it may be a catalyst for change within a robust therapeutic relationship, not a replacement for that relationship.

If you or someone you know is struggling with an eating disorder, support is available through the National Eating Disorders Association (NEDA) helpline (US: 1-800-931-2237) and Beat Eating Disorders (UK: 0808 801 0677).

Medical disclaimer: This page is educational information only and does not constitute medical advice. Eating disorders are serious medical conditions. Anyone with an eating disorder should work with a qualified medical team before making any decisions about psilocybin or any other intervention.